Use of the melanoma vaccine in 38 dogs: The South African experience

Abstract

The commercially available vaccine Oncept ^® is indicated for the management of dogs with stage II or III oral melanoma after local control has been achieved. Survival times in dogs with both oral and digit melanoma have been shown to be significantly increased following vaccination. This retrospective study was designed to document the investigators’ experiences with Oncept ^® vaccine when used as an adjunct therapy for treatment of stage II–IV oral, digit and malignant melanoma of other sites after local control had been achieved in dogs presented to a South African specialist referral veterinary practice. Thirty-eight dogs diagnosed with melanoma (25 oral, 6 digit and 7 infiltrative at various other sites) underwent a combination of surgical excision and Oncept ^® vaccination. At the end of the study period there were 16 live and 22 dead dogs; median survival time of the live dogs was 29 months (range 2–46 months) versus 8 months (range 2–16 months) for those that died from progressive disease. This study showed that by using a combination of surgical excision and vaccination with Oncept ^® survival times in dogs with malignant melanoma of the oral cavity, digit and other sites can be increased significantly.